Monopar Therapeutics Current Cash

Monopar Therapeutics (MNPR) currently reports a current cash of $53B as of March 2026. That compares with $40B in the prior-year period — up 32.3% year over year. Use the charts on this page to explore Monopar Therapeutics's current cash history and peer comparisons.

Monopar Therapeutics's current cash increased from $40B to $53B — a 32.3% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Monopar Therapeutics reported $53B in current cash as of March 2026. That compares with $40B in the prior-year period — up 32.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $53B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Monopar Therapeutics, and consider following MNPR for alerts when major investors trade the stock.

Monopar Therapeutics is classified in the Healthcare sector. On current cash, it currently shows $53B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MNPR with unrelated industries.